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Abstract 
 
Boron neutron capture therapy (BNCT) is a non-conventional type of radio-chemotherapy that 
has been used to target a number of cancers, although predominantly brain tumours (gliomas). 
We report the co-spray-drying of o-carborane, as a model BNCT agent, with 
poly(vinylpyrrolidone) (PVP), a water-soluble polymer, to produce microparticle powders of 
high boron-content for BNCT treatment of liver and lung cancers. The powders have been 
characterised using NMR, particle sizing, electron microscopy and cytotoxicity tests. 1H NMR 
indicated the high temperatures (180 °C) of the spray drying process did not degrade the PVP. 
Mean particle diameters (x90) were in the 2–10 µm range, with finer fractions being present (x10 
 1–2 µm), and were therefore considered suitable size for delivery to the lungs. SEM imaging 
showed particles to be spherical, with dimples and cavities, caused by the spray drier nozzle 
characteristics, and similarly sized irregularly-shaped crystalline particles, thought to be o-
carborane. Boron chemical mapping was attempted using EDS, although the low atomic weight 
of boron did not allow this to be possible. Cytotoxicity studies, using neoplastic (human 
glioblastoma U-87 MG) and non-neoplastic (human fetal lung fibroblast MRC-5) cells, revealed 
the PVP/o-carborane co-spray-dried particles to be non-toxic, as expected. 
Introduction 
 
Boron neutron capture therapy (BNCT) is a non-
conventional radio-chemotherapy technique that provides 
a way of selectively destroying malignant cells, sparing 
surrounding normal cells [1-3]. Boron (10B) has a large 
neutron capture cross-section and when the element is 
irradiated with low-energy (thermal) neutrons, a nuclear 
fission reaction occurs to yield high linear energy transfer 
(LET) α-particles (1.47 MeV) and recoiling 7Li nuclei 
(0.84 MeV), with only low energy  emission (478 keV) 
[4,5]. The penetration of α-particles and 7Li+ into 
surrounding tissues is only 8 and 5 µm, respectively, and 
so the highly-ionising energy dose is confined to the 
original 10B-containing cell or at least to the adjacent 
cells. Since the collateral damage is very low, this in 
principle, allows for a particularly targeted therapy. For 
this to occur, a sufficient quantity of 10B must be 
selectively localised into the cancer cells, and a sufficient 
dose of thermal neutrons aimed at the 10B-containing 
cancer cells (ca. 20–30 µg 10B/g tumour) [4,6]. 
BNCT has been mainly focused on treatment of brain 
tumours (gliomas), predominately for the historical 
reasons of low-energy thermal neutron beams having low 
penetration through tissues [7]. Other cancers, however, 
are increasingly being investigated, such as head and 
neck, lung and liver cancers [1,8-12]. Also, non-
malignant diseases, such as rheumatoid arthritis, are 
useful in BNCT treatment [13]. The high number of lung 
cancer incidences (1.6 million diagnoses pa) [14], prompt 
a wide-spectrum use of BNCT for this cancer type [15]. 
Diffuse, non-resectable tumours in the lung seem 
particularly attractive targets for BNCT [8], as does 
hepatocellular carcinoma, which has poor effective 
treatments and prognosis unless diagnosed at an early 
stage [10]. 
Carboranes, caged polyhedral molecules based on boron, 
exhibit high molar boron content, neutral charge and good 
stability and are therefore ideal candidate molecules for 
use in BNCT [5,6,16,17]. These molecules are highly 
hydrophobic [18], although can be chemically modified 
[19,20], exist in different forms (ortho- „o-‟, meta- „m-‟ or 
para „p-‟) [18] and are biocompatible [21]. 
Spray drying is a convenient, attractive, one-step method 
of producing particles (typically, 1–10 µm dia.) from a 
liquid feed [22-24]. The technique can be used to 
microencapsulate active drugs/particles within a carrier 
(excipient) [22-26] and therefore might be effective in 
producing carriers to transport BNCT agents to cancers, 
such as those of the liver or lung; treatment of gliomas 
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would require penetration through the blood-brain-barrier 
and therefore spray-dried particles would not be suitable 
owing to their large diameters [27]. In the case of liver 
cancer BNCT treatments, such formulations might be 
delivered orally or via injection since they are likely to 
end up in this organ. For lung cancer, delivery could be 
administered via metered-dose inhaler or dry powder 
inhaler (DPI) systems. Control of particle size, density 
and morphology can be achieved by varying spray drying 
operating conditions, such as air flow rate, inlet 
temperature, pump speed and feed concentration 
[22,23,28]. This is particularly useful for making DPI 
particulates [29,30], where the particle size broadly 
determines the locations within the airway the dispersed 
powders will be deposited [29,31]. For example, the 
smallest particles will end up in the alveoli, slightly larger 
ones will reach the bronchioles and the largest particles 
will only travel as far as the trachea. 
In this paper, o-carborane (an underivatised, model 
BNCT agent) has been co-spray dried with 
poly(vinylpyrrolidone) (PVP, povidone), a water-soluble 
polymer that is effective as a drug delivery vehicle for 
dispersions of microparticles [32-35], to produce powders 
that could be further investigated for use as BNCT 
treatments for liver and lung cancers. Powders were 
characterised using NMR, particle sizing, electron 
microscopy and cytotoxicity tests. 
 
Experimental 
 
Materials 
PVP (MW 360,000 g mol-1) was purchased from Sigma-
Aldrich (Dorset, UK); o-carborane and di-sodium 
tetraborate (Na2B4O7.10H2O) were obtained from Alfa 
Aesar, UK and ThermoFisher Scientific (Loughborough, 
UK), respectively. Distilled water (MilliQ, Merck 
Millipore, Billerica, MA, USA) was used to prepare 
PVP/o-carborane solutions to be spray-dried. The cell 
culture reagents trypsin, Dulbecco‟s Modified Eagle‟s 
Medium (DMEM), Fetal Bovine Serum (FBS) and 
Penicillin-Streptomycin (PS) were obtained from Gibco 
(ThermoFisher Scientific). 
 
Methods 
Spray drying 
Aqueous solutions of PVP (1 and 2 %w/v) with and 
without o-carborane (0.2 %w/v) were prepared (100 mL, 
50 mL for o-carborane containing solutions) for spray 
drying (Table 1). Solutions were agitated (3000 rpm, 
electronic mini shaker) until all solids had dissolved (ca. 
1 h) and left overnight (16 h). Spray drying was 
performed using a Buchi B-290 spray drier (Buchi, 
Manchester, UK) using high inlet temperature (180 oC) 
and low outlet temperature (130 oC, recorded not 
controlled) conditions; other spray drying conditions were 
kept constant (air flow rate 52 mm, aspirator 100%, pump 
speed 10 %, nozzle cleaner setting 3). After spray drying, 
% recovery for each run was calculated and the powders 
stored in vials in a desiccator. 
 
NMR 
1H NMR spectra were obtained using a JEOL Eclipse+ 
400 MHz NMR instrument (Oxford Instruments, Oxford, 
UK), operating at a field strength of 9.389766 T. PVP and 
o-carborane samples were dissolved in either CDCl3 or 
CH3OD. 
 
Particle sizing 
Particle sizing was performed on the spray-dried powder 
PVP and PVP/o-carborane samples. The powders were 
dispersed using compressed air (2 bar) via the RODOS 
dry powder dispenser (RODOS, Sympatec GmbH 
Germany) prior to sizing analysis with a Sympatec 
HELOS laser diffractometer (HELOS Sympatec). The 
particle size distribution was recorded as x10, x50 and x90 
values using WINDOW 4.0 software (Sympatec). The 
values presented were the mean of triplicate runs. 
Statistical analysis was performed using IBM Statistics 
SPSS (Version 21; Armonk, NY, USA) using a one-way 
ANOVA and post-hoc analysis (Tukey test). 
 
SEM and EDS 
Dry powders were sprinkled onto double-sided, carbon-
loaded disks attached to nickel SEM stubs. Excess 
powder was removed using a N2 stream and the samples 
were then sputter-coated with Au/Pd in an Argon 
atmosphere (<0.2 Torr, 18 mA for 5–10 min; Polaron 
E5000 SEM coating-unit, Quorum Technologies Ltd., 
East Grinstead, UK). SEM imaging was performed 
immediately using a JEOL JSM-6060LV SEM instrument 
(resolution = 4.5 nm, acceleration voltage=15 kV). EDS 
(Inca Oental FET×3 with high-angle, ultra-thin window 
Si(Li) detector; Oxford Instruments) analysis was also 
undertaken on some of the samples investigated by SEM. 
A spot size of 60 and a working distance of 11 was used 
for EDS. 
 
Tissue culture and cytotoxicity studies 
Human glioblastoma U-87 MG (cancer cell line) and 
human fetal lung fibroblast MRC-5 (normal cell line) 
cells were grown in culture at 37 oC in DMEM, 
supplemented with FBS (10 %v/v), penicillin (100 
μg/mL), streptomycin (100 μg/mL) in a humidified 
atmosphere containing CO2 (5 %v/v). The medium was 
changed every 2–3 days and cells were sub-cultured by 
trypsinisation before reaching ~80 % confluency in tissue 
culture flasks. 
The effect of PVP/o-carborane materials (#2, #8 and #11; 
Table 1) on U-87 MG and MRC-5 cell proliferation 
capacity and viability was assessed in vitro. These 
samples were diluted in DMEM and homogenised prior 
to their addition in cell cultures. Briefly, cells at an initial 
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density of 105 cells/mL were seeded in a 24-well tissue 
culture plate. After 2 h following cell attachment to the 
substrate of the plate, material suspensions were added at 
various concentrations (0.1, 0.5 and/or 1.0 mg/mL) before 
cells were allowed to further grow for 48 h. At this point, 
cells were detached by trypsinisation and the cell density 
(number of cells/mL) determined using a Neubauer plate 
(cell counting plate). Cell proliferation was expressed as 
% cell growth compared to control-untreated cell 
cultures. Cellular death was also assessed using the 
trypan-blue dye exclusion method and reported as cell 
viability (% trypan blue negative cells in culture) [36]. 
The data presented were calculated based on at least four 
separate measurements from two biological replicate 
experiments. 
 
Table 1. Samples for spray drying and instrument inlet 
temperature settings 
Sample 
number 
Product w/v
% 
PVP 
w/v% o-
carborane 
Inlet 
temp. 
°C 
#1 PVP 2 0 180 
#2 PVP 2 0 180 
#3 PVP 2 0 180 
#4 PVP 2 0 180 
#5 PVP 2 0 130 
#6 PVP 2 0 130 
#7 PVP 2 0 130 
#8 PVP 1 0 180 
#9 PVP 1 0 180 
#10 PVP 1 0 180 
#11 PVP + o-carborane 2 0.2 180 
#12 PVP + o-carborane 2 0.2 180 
#13 PVP + o-carborane 2 0.2 180 
 
Results and Discussion 
 
Spray Drying 
Spray drying successfully produced white, fine powdered 
products of PVP/o-carborane (Table 2). Lower % yields 
(% recoveries) were obtained using 1 w/v% PVP (5.7±3.5 
%) than when using 2 w/v% PVP (30.1±1.4 %) and 
consequently, co-spray-dried formulations using o-
carborane were carried using the higher PVP 
concentration; similar %yields were obtained (32.4±9.8 
%; all using an inlet temperature of 180 °C). A small 
decrease in % yield was found when the inlet temperature 
was decreased from 180 °C (30.1±1.4 %) to 130 °C 
(23.0±11.0 %; Table 2). 
 
1H NMR of PVP/o-carborane 
To check that the integrity of PVP had not been 
compromised during the spray drying process, 1H NMR 
experiments were performed. The literature spectrum was 
also obtained and used to help assign peaks [37]. The 
spectra before and after spray drying, both in the absence 
of o-carborane, looked very similar (Figure 1). The signal 
corresponding to H3 appeared slightly differently in that 
the sharp, single peak within the doublet shifted slightly 
upfield. This may be associated with hydrogen bonded 
water, as spray drying is known to produce hygroscopic, 
very fine amorphous powders. Peaks H1, H2, H4 and H5 
were very similar to those in the literature [37], 
suggesting the PVP was unaffected by the spray drying 
process, as might be expected since there have been 
numerous reports on the spray drying of this material [38-
40]. 
 
Table 2. %Yields obtained for various spray-dried 
formulations 
Sample number %Yield Mean±SD %Yield 
#1 31.0 30.1±1.4  
#2 28.0  
#3 30.5  
#4 31.0  
#5 20.5 23.0±11.0 
#6 35.0  
#7 13.5  
#8 6.0 5.7±3.5 
#9 2.0  
#10 9.0  
#11 28.2 32.4±9.8 
#12 43.6  
#13 25.5  
 
 
 
Figure 1. 1H NMR spectra of ‘as received’ o-carborane 
(blue), ‘as received’ PVP (green), spray-dried PVP (2 
%w/v; brown) and co-spray-dried PVP (2 %w/v) with o-
carborane (0.2 %w/v; purple). Labels refer to hydrogen 
atoms in the PVP structure shown, with peak 
assignments having been made in [37]. 
 
1H NMR spectra of co-spray-dried PVP/o-carborane and 
„as received‟ o-carborane were also obtained to see 
whether o-carborane could be detected in the co-spray-
dried powder and, if so, to ascertain whether its chemical 
structure had been modified (Figure 1). The multitude of 
peaks observed in the pure o-carborane were not apparent 
in the co-spray-dried product. This was probably due to 
the high molecular weight of PVP, however, with the 
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spectrum being swamped with the backbone CH2 and 
pendant pyrrolidone signals relative to the o-carborane 
BH and CH signals. Also, o-carborane was only present 
at 10 %w/v of the PVP content. Thus, the 1H NMR data 
were inconclusive as to whether the o-carborane had been 
incorporated into the microparticles. The technique did 
establish, however, that PVP was unchanged by the 
spray-drying process, and particularly by the high 
temperatures (180 °C) involved. 
 
Particle sizing 
Particle diameters for the spray-dried products were 
obtained from laser diffraction histogram plots (Figure 2). 
The mean x10, x50 and x90 particle diameters (n=3) were 
obtained from these profiles for spray-dried PVP and 
PVP/o-carborane samples (Figure 3). The xn value refers 
to the particle diameter exhibited by n % of the particles; 
i.e., for x10, 10% of the particles will have a diameter x. 
The x50 and x90 are also given, which have similar 
definitions, and have progressively larger values since 
more of the particles will have these particular size 
thresholds. The „bell-shaped‟ curve („envelope‟, Figure 
2), noting the log-scale axis, can have shoulders on either 
side of the peak maximum; shoulders on the right of the 
maximum almost always are an indication of 
agglomerated particles. Repeating the sizing 
measurement at higher pressures can reduce this effect. 
 
 
Figure 2. An example Sympatec particle size distribution 
output plot from sample #1 run 1 of 3; x10 = 1.31 µm; x50 
= 3.47 µm; x90 = 8.48 µm; SMD = 2.50 µm; x16 = 1.65 µm; 
x84 = 7.15 µm; x99 = 13.43 µm; SV = 2.40 m²/cm³; Sm = 
23973.67 cm²/g. Two plots are displayed: a particle 
diameter frequency plot and a cumulative frequency (‘S-
shaped’) curve of particle size from which median and 
interquartile range data is automatically generated. In 
this example, the mean particle diameter is ca. 3 m, 
although finer particles (‘fines’) and larger particles, the 
latter of which may be agglomerates, can be observed. 
 
The x90 data shows that mean particle diameters were ca. 
2–10 µm, although #11 was 17.27±3.77 µm. No statistical 
differences (p>0.05) were observed between different 
batches of spray-dried PVP (#1 to #4), in the absence of 
o-carborane, using an inlet temperature of 180 °C. When 
this temperature was decreased to 130 °C, again, no 
significant differences (p>0.05) in x90 values were 
observed compared to the higher temperature products, 
although batch differences were seen between #1 and #7 
(p<0.05), and #2 and #7 (p<0.05) only. Statistical 
differences between x90 values were also generally not 
observed (p>0.05) when the PVP concentration was 
lowered to 1 %w/v. When PVP was co-spray-dried with 
o-carborane, x90 values were unaffected (p>0.05), 
although for #11, x90 values were all much higher (p<0.01 
or p<0.001) than all the other samples. The reason for this 
batch variation is uncertain, but may be due to variations 
in humidity perhaps causing agglomeration. 
 
Figure 3. Mean particle diameters of spray-dried PVP 
and co-spray-dried PVP/o-carborane samples: red = x10, 
green = x50, blue = x90 values; particles determined using 
spray drying (mean ± SD, n = 3). 
 
Particle sizes characterised by x50 and x10 values followed 
a very similar trend to the x90 values; x10 sizes were much 
less than x50 and, in turn, less than x90 sizes, due to the 
definition of the xn term. 
 
Morphology 
The morphology of the spray-dried powders of PVP with 
and without o-carborane was investigated using SEM. 
Prior to this, imaging of the „as received‟ PVP and o-
carborane was performed (Figure 4). The former 
consisted of large, smooth-sided crystals with dimensions 
typically in the 100–500 µm range (Figure 4a,b). The 
particles of o-carborane appeared smaller, 5–100 µm 
(Figure 4c,d). 
SEM images of spray-dried PVP, produced in the absence 
of o-carborane and using an inlet temperature of 180 °C, 
all showed small, rounded particles of relatively uniform 
size (< 5 µm; Figure 4e). Dimples and hollows in the 
particles were observed and have been encountered in 
numerous other spray-dried products [22]: they are 
thought to result from the nozzle characteristics as the 
emerging droplet is formed [41]. The particle surfaces 
appeared smooth, although in some cases, smaller 
particles were attached, possibly being due to inter-
particulate forces or capillary forces causing 
agglomeration. No obvious differences in morphology 
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were seen between different batches of spray-dried PVP 
(samples #1 to #4, not shown). No obvious changes in 
morphology or particle size were observed when the inlet 
temperature was reduced to 130°C (not shown), in 
agreement with the particle size data. 
 
Figure 4. SEM images of (a,b) ‘as received’ PVP, (c,d) ‘as 
received’ o-carborane, (e) spray-dried PVP (sample #4, 
inlet temperature 180 °C), (f) co-spray-dried PVP/o-
carborane (sample #13, inlet temperature 180 °C); 
magnification (a) 100×, (b) 2200×, (c) 100×, (d) 800×, (e) 
2200×, (f) 2200×. 
 
SEM imaging of PVP co-spray-dried with o-carborane 
(Figure 4f), in agreement with the particle sizing data, 
generally showed similarly sized particles, although some 
particles were larger than 10 µm. In some of the SEM 
images of the co-spray-dried product, small irregularly-
shaped crystalline particles were seen, which were not 
encountered in the pure spray-dried PVP products. These 
crystals appeared to be similar to those seen in the „as 
received‟ o-carborane material (Figure 4d). It may be that 
the o-carborane, which is not water-soluble, although 
assisted to form suspensions by the viscosity/swelling of 
the PVP, was largely unchanged by the spray drying 
process. A less-magnified image of the PVP/o-carborane 
spray-dried product revealed there to be a significant 
number of such small crystals, thought to be o-carborane; 
these were not apparent in similar images of pure spray-
dried PVP (not shown). The extent of this phase 
separation is unknown. To address this situation, EDS 
mapping was attempted. The assumption was that if the 
PVP was intimately mixed with o-carborane, a boron 
chemical map would appear very similar to the SEM 
image. However, the boron signal was quite low and 
darker depressions marked regions where the particles 
resided, suggesting that the boron content was less than 
on the double-sided, adhesive, carbon tape. It is known 
that elements with atomic masses below carbon are often 
not shown in EDS studies and therefore this might 
explain the absence of boron in the EDS map of the co-
spray-dried particles. This was verified by attempting to 
obtain boron maps from di-sodium tetraborate, where 
again, no contrast was observed from the low atomic 
mass element. 
 
Cytotoxicity studies 
To check for cytotoxicity, the spray-dried powders (PVP 
#2 and #8, and PVP/o-carborane #11) were exposed to 
neoplastic (human glioblastoma U-87 MG) and non-
neoplastic (human fetal lung fibroblast MRC-5) cells. 
Cell proliferation and cell death were determined over a 
range of PVP/o-carborane concentrations (0–1.0 mg/mL; 
Figure 5). In all cases, cell proliferation did not fall below 
87% and values were otherwise greater than 90%. 
Similarly, the highest cell death value was only 2.5%. No 
obvious change in cellular morphology, cell proliferation 
or cell death was noted over the duration of the 
experiment (48 h). Therefore, the PVP/o-carborane co-
spray-dried product was described as being non-cytotoxic 
at the concentrations investigated. This is in agreement 
with the known low toxicity data of the constituent PVP 
[42,43] and o-carborane [44] compounds. 
 
Figure 5. Effect of spray-dried PVP (samples #2 and #8) 
and co-spray-dried PVP/o-carborane (sample #11) on (a) 
cell proliferation and (b) cell death; blue = U-87 MG 
cells, orange = MRC-5 cells. 
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Conclusions 
 
In this paper, PVP (2 %w/v)/o-carborane (0.2 %w/v) 
spray-dried microparticles were produced with the aim 
providing a boron-delivery system for use in BNCT 
treatment of liver and lung cancers. 1H NMR studies 
revealed the high temperatures (180 °C) of the spray 
drying process did not degrade the constituent PVP. Mean 
particle diameters (x90) were in the 2–10 µm range, with 
finer fractions being present (x10  1–2 µm), and the 
particles were therefore considered suitable for delivery 
to the lungs. The particle sizes were in the micrometre 
range (too large to cross the blood-brain-barrier) and 
therefore would not be of use for the BCNT treatment of 
brain tumours. Further optimisation of particle sizes could 
be carried out to decrease x90, for example, by changing 
air and liquid flow conditions. SEM imaging showed the 
particles to be spherical, with dimples and cavities caused 
by the spray drier nozzle characteristics, as typical with 
the spray drying process. Some small irregularly-shaped 
crystalline particles, thought to be o-carborane, were 
observed by SEM, although the proportion accounted for 
less than that in the formulation (10 %w/w). An attempt 
was made to map the boron content in spray-dried 
powders on a surface using EDS, although the low atomic 
weight of boron made detection not possible. Cytotoxicity 
studies, using neoplastic (human glioblastoma U-87 MG) 
and non-neoplastic (human fetal lung fibroblast MRC-5) 
cells, revealed the PVP/o-carborane co-spray-dried 
particles to be non-toxic, as expected. 
 
References 
 
1. Moss RL: Critical review, with an optimistic outlook, on boron neutron 
capture therapy (BNCT). Applied Radiation and Isotopes 2014; 88:2-11. 
2. Locher GL: Biological effects and therapeutic possibilities of neutrons. 
The American Journal of Roentgenology and Radium Therapy 1936; 
36(1):1-13. 
3. Masoudi SF, Rasouli FS and Ghasemi M: BNCT of skin tumors using the 
high-energy D-T neutrons.Applied Radiation and Isotopes 2017; 122:158-
163. 
4. Barth RF, Coderre JA, Vicente MGH and Blue TE: Boron neutron capture 
therapy of cancer:Current status and future prospects. Clinical Cancer 
Research 2005; 11(11):3987-4002. 
5. Hosmane NS, Yinghuai Z, Maguire JA, Kaim W and Takagaki M: Nano 
and dendritic structured carboranes and metallacarboranes: From 
materials to cancer therapy. Journal of Organometallic Chemistry 2009; 
694(11):1690-1697. 
6. Hawthorne MF: New horizons for therapy based on the boron neutron 
capture reaction. Molecular Medicine Today 1998; 4(4):174-181. 
7. Andoh T, Fujimoto T, Suzuki M, Sudo T, Sakurai Y, Tanaka H, Fujita I, 
Fukase N, Moritake H, Sugimoto T, Sakuma T, Sasai H, Kawamoto T, 
Kirihata M, Fukumori Y, Akisue T, Ono K and Ichikawa H: Boron 
neutron capture therapy (BNCT) as a new approach for clear cell sarcoma 
(CCS) treatment: Trial using a lung metastasis model of CCS.Applied 
Radiation and Isotopes 2015; 106:195-201. 
8. Trivillin VA, Garabalino MA, Colombo LL, Gonzalez SJ, Farias RO, 
Monti Hughes A, Pozzi ECC, Bortolussi S, Altieri S, Itoiz ME, 
Aromando RF, Nigg DW and Schwint AE: Biodistribution of the boron 
carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) 
for boron neutron capture therapy (BNCT) in an experiment model of 
lung metastases.Applied Radiation and Isotopes 2014; 88:94-98. 
9. Andoh T, Fujimoto T, Suzuki M, Sudo T, Sakurai Y, Tanaka H, Fujita I, 
Fukase N, Moritake H, Sugimoto T, Sakuma T, Sasai H, Kawamoto T, 
Kirihata M, Fukumori Y, Akisue T, Ono K and Ichikawa H: Boron 
neutron capture therapy (BNCT) as a new approach for clear cell sarcoma 
(CCS) treatment: Trial using a lung metastasis model of CCS. Applied 
Radiation and Isotopes 2015; 106:195-201. 
10. Chou FI, Chung HP, Liu HM, Chi CW and Lui WY: Suitability of boron 
carriers for BNCT: Accumulation of boron in malignant and normal liver 
cells after treatment with BPA, BSH and BA. Applied Radiation and 
Isotopes 2009; 67:S105-S108. 
11. Liao AH, Chou FI, Kuo YC, Chen HW, Kai JJ, Chang CW, Chen FD and 
Hwang JJ: Biodistribution of phenylboric acid derivative entrapped 
lipiodol and 4-borono-2-18F-fluoro-L-phenylalanine-fructose in GP7TB 
liver tumor bearing rats for BNCT. Applied Radiation and Isotopes 2010; 
68:422-426. 
12. Zonta A, Pinelli T, Prati U, Roveda L, Ferrari C, Clerici AM, Zonta C, 
Mazzini G, Dionigi P, Altieri S, Bortolussi S, Bruschi P and Fossati F: 
Extracorporeal liver BNCT for the treatment of diffuse metastases: What 
was learned and what is still to be learned. Applied Radiation and 
Isotopes 2009; 67:S67-S75. 
13. Valliant JF, Schaffer P, Britten JF, Davison A, Jones AG and Yanch JC: 
The synthesis of corticosteroid-carborane esters for the treatment of 
rheumatoid arthritis via boron neutron captures synovectomy. 
Tetrahedron Letters 2000; 41(9):1355-1358. 
14. Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de 
Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, 
Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, 
Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, 
Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, 
Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, 
Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR and Pass 
HI: Scientific Advances in Lung Cancer. Journal of Thoracic Oncology 
2015; 11(5):613-638. 
15. Farias RO, Bortolussi S, Menendez PR and Gonzalez SJ: Exploring boron 
neutron capture therapy for non-small cell lung cancer. Physica Medica 
2014; 30(8):888-897. 
16. Kawasaki R, Sasaki Y and Akiyoshi K: Intracellular delivery and passive 
tumor targeting of a self-assembled nanogel containing carborane clusters 
for boron neutron capture therapy. Biochemical and Biophysical Research 
Communications 2017; 483(1):147-152. 
17. Calabrese G, Nesnas JJ, Barbu E, Fatouros D and Tsibouklis J: The 
formulation of polyhedral boranes for the boron neutron capture therapy 
of cancer. Drug Discovery Today 2012; 17(3/4):153-159. 
18. Ohta K, Goto T, Fujii S, Kawahata M, Oda A, Ohta S, Yamaguchi K, 
Hirono S and Endo Y: Crystal structure, docking study and structure-
activity relationship of carborane-containing androgen receptor antagonist 
3-(12-hydroxymethyl-1,12-dicarba-closo-dodecaboran-1yl)benzonitrile. 
Bioorganic and Medicinal Chemistry 2011; 19(11):3540-3548. 
19. Anderson BD: Prodrugs for improved CNS delivery. Advanced Drug 
Delivery Reviews 1996; 19(2):171-202. 
20. Hoste K, De Winne K and Schacht E: Polymeric prodrugs. International 
Journal of Pharmaceutics 2004; 277(1-2):119-131. 
21. Di Meo C, Panza L, Campo F, Capitani D, Mannina L, Banzato A, 
Rondina M, Rosato A and Crescenzi V: Novel types of carborane-carrier 
hyaluronan derivatives via “click chemistry”. Macromolecular Bioscience 
2008; 8(7):670-681. 
22. Shur J, Nevell TG, Shute JK and Smith JR: The spray drying of 
unfractionated heparin: optimisation of the operating parameters. Drug 
Development and Industrial Pharmacy 2008; 34(6):559-568. 
23. Shur J, Nevell TG, Ewen RJ, Price R, Smith A, Barbu E, Conway JH, 
Carroll MP, Shute JK and Smith JR: Co-spray-dried unfractionated 
heparin with L-leucine as a dry powder inhaler mucolytic for cystic 
fibrosis therapy. Journal of Pharmaceutical Sciences 2008; 97(11):4857-
4868. 
24. Okuyama K, Abdullah M, Lenggoro IW and Iskandar F: Preparation of 
functional nanostructured particles by spray drying. Advanced Powder 
Technology 2006; 17(6):587-611. 
25. Desai KGH and Jin Park H: Recent developments in microencapsulation 
of food ingredients. Drying Technology 2005; 23(7):1361-1394. 
26. Gharsallaoui A, Roudaut G, Chambin O, Voilley A and Saurel R: 
Applications of spray-drying in microencapsulation of food ingredients: 
An overview. Food Research International 2007; 40(9):1107-1121. 
27. Pardridge WM: Non-invasive drug delivery to the human brain using 
endogenous blood-brain-barrier transport systems. Pharmaceutical 
Science and Technology Today 1999; 2(2):49-59. 
28. Rattes ALR and Oliveira WP: Spray drying conditions and encapsulating 
composition effects on formation and properties of sodium diclofenac 
microparticles. Powder Technology 2007; 171(1):7-14. 
James R. Smith et al., JIPBS, Vol 4 (4), 09-15, 2017 
15 
29. Pilcer G and Amighi K: Formulation strategy and use of excipients in 
pulmonary drug delivery. International Journal of Pharmaceutics 2010; 
392(1):1-19. 
30. Anderson PJ: Delivery options and devices for aerosolized therapeutics. 
Chest Journal 2001; 120(3 suppl):89S-93S. 
31. Steckel H and Brandes HG: A novel spray-drying technique to produce 
low density particles for pulmonary delivery. International Journal of 
Pharmaceutics 2004; 278(1):187-195. 
32. Kanaze FI, Kokkalou E, Niopas I, Georgarakis M, Stergiou A and 
Bikiaris D: Dissolution enhancement of flavonoids by solid dispersion in 
PVP and PEG matrixes: A comparative study. Journal of Applied 
Polymer Science 2006; 102(1):460-471. 
33. Papageorgiou GZ, Bikiaris D, Kanaze FI, Karavas E, Stergiou A and 
Georgarakis E: Tailoring the release rates of fluconazole using solid 
dispersions in polymer blends. Drug Development and Industrial 
Pharmacy 2008; 34(3):336-346. 
34. Fischer F and Bauer S: Polyvinylpyrrolidon. Ein Tausendsassa in der 
Chemie, Chemie in unserer Zeit 2009; 43(6):376-383. 
35. Gohel M, Patel M, Amin A, Agrawal R, Dave R and Bariya N: 
Formulation design and optimization of mouth dissolve tablets of 
nimesulide using vacuum drying technique. AAPS PharmSciTech 2004; 
5(3):10-15. 
36. Vizirianakis IS and Tsiftsoglou AS: Blockade of murine erythroleukemia 
cell differentiation by hypomethylating agents causes accumulation of 
discrete small poly(A)-RNAs hybridized to 3'-end flanking sequences of 
β major globin gene. Biochimica et Biophysica Acta 2005; 1743(1-
2):101-114. 
37. Luan YX, Song AX and Xu GY: Location of probe molecule in double-
chain surfactant aggregates in absence and presence of water-soluble 
polymer by NMR. Soft Matter 2009; 5(13):2587-2595. 
38. Mahlin D, Berggren J, Gelius U, Engstrom S and Alderborn G: The 
influence of PVP incorporation on moisture-induced surface 
crystallization of amorphous spray-dried lactose particles. International 
Journal of Pharmaceutics 2006; 321(1-2):78-85. 
39. Kim MJ, Lee JH, Yoon H, Kim SJ, Jeon DY, Jang JE, Lee D and Khang 
G: Preparation, characterization and in vitro dissolution of aceclofenac-
loaded PVP solid dispersions prepared by spray drying or rotary 
evaporation method. Journal of Pharmaceutical Investigation 2013; 
43(2):107-113. 
40. Yuan XD, Sperger D and Munson EJ: Investigating miscibility and 
molecular mobility of nifedipine-PVP amorphous solid dispersions using 
solid-state NMR spectroscopy. Molecular Pharmaceutics 2014; 
11(1):329-337. 
41. Masters K: Spray Drying Handbook, 1985, New York, Longman 
Scientific & Technical. 
42. Bourlinos AB, Georgakilas V, Zboril R, Steriotis TA, Stubos AK and 
Trapalis C: Aqueous-phase exfoliation of graphite in the presence of 
polyvinylpyrrolidone for the production of water-soluble graphenes. Solid 
State Communications 2009; 149(47-48):2172-2176. 
43. Liu Q, Zhu X, Huo ZH, He XL, Liang Y, Xu MT: Electrochemical 
detection of dopamine in the presence of ascorbic acid using 
PVP/graphene modified electrodes. Talanta 2012; 97:557-562. 
44. Theodoropoulos D, Rova A, Smith JR, Barbu E, Calabrese G, 
Vizirianakis IS, Tsibouklis J and Fatouros DG: Towards boron neutron 
capture therapy: The formulation and preliminary in vitro evaluation of 
liposomal vehicles for the therapeutic delivery of the dequalinium salt of 
bis-nido-carborane. Bioorganic and Medicinal Chemistry Letters 2013; 
23(22):6161-6166. 
 
